Does Medicare Advantage Cover Leqvio (Inclisiran)?

How Medicare Advantage Plans Handle Leqvio Coverage

Medicare Advantage (MA) plans cover drugs through two separate benefit structures, and which one applies to Leqvio shapes everything about cost and access. Under Part D (the pharmacy benefit), most MA plans do not list inclisiran on their formularies for 2025. Under Part B (the outpatient medical benefit), coverage is more common because inclisiran is not self-administered. The drug is injected by a clinician, placing it in the same administrative category as infused biologics.

The FDA approved inclisiran (Leqvio) on December 22, 2021, for adults with established atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who need additional LDL-C lowering beyond maximally tolerated statin therapy [1]. That indication drives every coverage decision downstream.

The key data supporting approval came from ORION-10 and ORION-11. In ORION-10 (N=1,561, patients with ASCVD), inclisiran 284 mg reduced LDL-C by 52.3% from baseline versus a 1.0% increase with placebo at day 510 (P<0.0001) [2]. ORION-11 (N=1,617, mixed ASCVD and high-risk patients) showed a 49.9% LDL-C reduction at day 510 (P<0.0001) [2]. These reductions persist on a twice-yearly dosing schedule, which is clinically distinct from the monthly or every-two-weeks injection schedules required by the PCSK9 monoclonal antibodies evolocumab (Repatha) and alirocumab (Praluent).

The American College of Cardiology (ACC) 2022 expert consensus states that PCSK9 inhibitors, including inclisiran, are appropriate add-on therapy when LDL-C remains >70 mg/dL in very-high-risk ASCVD patients despite maximally tolerated statin plus ezetimibe [3]. That threshold is also the most commonly cited documentation requirement in MA prior authorization criteria.

Part B vs. Part D: Which Benefit Covers Inclisiran

This distinction determines your out-of-pocket cost more than any other single factor. Part B covers drugs that are not usually self-administered and are given in a physician's office or outpatient clinic [4]. Inclisiran qualifies because it requires clinician administration. If your MA plan covers inclisiran under Part B, you typically pay 20% of the Medicare-approved amount after your Part B deductible, once Medicare's 80% coinsurance kicks in.

Part D coverage, by contrast, requires the plan to include the drug on its formulary. In 2025, a review of publicly available CMS plan finder data shows that fewer than 15% of MA-PD plans list inclisiran at any formulary tier. When it does appear, it is usually placed on a specialty tier (Tier 5 or Tier 6), with cost sharing that can exceed $900 per dose before any secondary coverage applies.

CMS guidance on Part B vs. Part D classification for physician-administered drugs is codified in the Medicare Benefit Policy Manual, Chapter 15 [4]. Plans are permitted but not required to cover inclisiran under Part B, so confirming your specific plan's policy before each injection is necessary.

The decision tree a prescriber or patient should follow looks like this:

1. Call the MA plan's provider line and ask whether inclisiran is covered under the medical (Part B) benefit or the pharmacy (Part D) benefit for your specific plan ID.
2. If Part B: obtain a coverage determination letter confirming the diagnosis code (Z82.49 for family history of ischemic heart disease, I25.10 for ASCVD, or E78.01 for familial hypercholesterolemia) before scheduling the injection.
3. If Part D only: submit a formulary exception request with documentation of statin therapy, LDL-C lab values, and ASCVD or HeFH diagnosis.
4. If denied at both benefit levels: proceed to the appeal pathway described below.

Prior Authorization Criteria on Medicare Advantage Plans

Virtually every MA plan that covers inclisiran requires prior authorization (PA). The criteria are not standardized across carriers, but a consistent set of requirements appears across major plans including UnitedHealthcare, Humana, Aetna/CVS, Cigna-HealthSpring, and Anthem BlueCross.

Standard PA criteria typically include all of the following:

• Confirmed diagnosis of ASCVD (prior MI, stroke, or symptomatic peripheral arterial disease) or HeFH (defined by a Dutch Lipid Clinic Network score >8 or genetic confirmation)
• Documented use of maximally tolerated statin therapy for at least 8 to 12 weeks
• LDL-C >70 mg/dL (very-high-risk ASCVD) or >100 mg/dL (HeFH) despite statin plus ezetimibe
• Prescriber attestation that the drug will be administered in a clinical setting

The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol defines very-high-risk ASCVD as a history of multiple major ASCVD events or one major event plus multiple high-risk conditions [5]. MA plans lean on that definition when writing PA criteria.

For heterozygous FH specifically, the European Atherosclerosis Society consensus document estimated a population prevalence of approximately 1 in 250 adults [6]. That prevalence figure is relevant in appeal letters because it helps document that HeFH is a recognized, prevalent medical condition, not an experimental indication.

PA approvals, when granted, are typically valid for 12 months and require re-authorization annually. The prescribing clinician's office should submit the PA request with CPT codes 96372 (therapeutic injection) and J-code J3490 or the specific J-code once assigned, along with supporting lab work dated within 90 days.

Step Therapy: What Plans Require Before Approving Inclisiran

Step therapy is the central barrier. Most MA plans require documented failure of, or contraindication to, at least one PCSK9 monoclonal antibody before approving inclisiran. The two available options are evolocumab (Repatha, 140 mg every 2 weeks or 420 mg monthly) and alirocumab (Praluent, 75 to 150 mg every 2 weeks) [7][8].

"Failure" in this context means either an inadequate LDL-C response after 12 weeks of therapy at the labeled dose, or documented intolerance (typically musculoskeletal adverse effects or injection-site reactions severe enough to require discontinuation). Adverse events must be documented in the medical record with dates, not just noted in the PA request letter.

This requirement is clinically controversial. Inclisiran's twice-yearly administration schedule is a meaningful adherence advantage over biweekly monoclonal antibodies. A 2023 analysis published in the Journal of the American College of Cardiology noted that real-world persistence rates for biweekly PCSK9 monoclonal antibodies drop to approximately 50% at 12 months, compared with projected persistence above 80% with twice-yearly administration [9]. That data point is useful when writing a medical necessity letter arguing that step therapy through a biweekly injectable is not clinically equivalent.

Some plans exempt patients from the PCSK9 monoclonal antibody step if the patient has documented statin intolerance plus ezetimibe intolerance, and LDL-C remains severely elevated (>190 mg/dL). Check your specific plan's exception language before assuming step therapy is mandatory.

Formulary Tier and Cost Sharing on Medicare Advantage

When inclisiran appears on a Part D formulary, it is almost always placed on Tier 5 (specialty) or a non-preferred specialty tier. CMS data from the 2025 plan year shows specialty tier cost sharing commonly ranging from 25% to 33% coinsurance with no fixed copay cap at point of sale, before the catastrophic coverage phase applies [10].

Under the Inflation Reduction Act (IRA) provisions effective January 1, 2025, Medicare Part D out-of-pocket costs for covered drugs are capped at $2,000 per calendar year [11]. Once a beneficiary reaches that cap, cost sharing drops to $0 for the remainder of the plan year. For a drug with two doses per year at roughly $3,250 per dose, the IRA cap becomes highly relevant: a patient who reaches $2 to 000 in total Part D spending will pay nothing for subsequent doses that year.

The $2,000 IRA cap applies only to drugs that are actually covered on the formulary. For non-formulary drugs, you must first win a formulary exception before the cap applies. This is one more reason to pursue the appeal pathway rather than abandoning coverage.

How to Appeal a Medicare Advantage Denial of Leqvio

A denial is not a final answer. Federal law gives MA beneficiaries a structured appeal process with enforceable deadlines [12].

Level 1: Organization determination. Request a coverage determination in writing from the plan. For a non-urgent drug denial, the plan has 72 hours to respond to an expedited request or 14 days for a standard request [12].

Level 2: Internal appeal (redetermination). If denied, request a redetermination. Submit a letter of medical necessity from the prescribing physician that documents the indication, prior therapy tried and failed, current LDL-C with lab date, and the specific guideline citation (ACC/AHA 2018 [5]) supporting the prescription. The plan has 7 days (expedited) or 14 days (standard) to respond.

Level 3: Independent Review Entity (IRE). If the internal appeal fails, the case goes to MAXIMUS Federal Services, the CMS-contracted IRE. MAXIMUS must issue a decision within 72 hours (expedited) or 7 days (standard) [12]. MAXIMUS overturns MA drug denials in approximately 40 to 50% of cases when the appeal is supported by clinical documentation, based on CMS annual IRE report data [13].

Levels 4 and 5: After MAXIMUS, appeals escalate to the Office of Medicare Hearings and Appeals (OMHA) and then the Medicare Appeals Council. These levels are slower (60 to 90 days each) but remain viable for high-cost drugs.

A well-constructed Level 2 redetermination letter should include:

• The patient's primary diagnosis with ICD-10 code
• Current LDL-C (with date and reference range)
• Names, doses, and durations of all statins tried
• Names, doses, and durations of any PCSK9 monoclonal antibodies tried (or a documented reason they were not tried)
• The specific ACC/AHA guideline statement supporting inclisiran use [5]
• ORION-10 and ORION-11 efficacy data as clinical evidence [2]

Leqvio for Weight Loss: Not a Covered Indication

Inclisiran has no FDA-approved indication for weight loss. The drug targets PCSK9 messenger RNA in hepatocytes to reduce LDL-C receptors' degradation rate, a mechanism unrelated to appetite regulation or adipose metabolism [1]. Medicare Advantage plans cannot cover weight-loss drugs under Part D unless the drug carries an approved cardiovascular outcomes indication (a rule that currently applies to semaglutide 2.4 mg per a 2024 CMS decision, not to inclisiran) [14].

Any PA request citing weight loss as the indication for Leqvio will be denied automatically. The correct indications to cite are ASCVD or HeFH, as specified in the FDA label [1].

Manufacturer Savings Cards and Patient Assistance: Medicare Restrictions

Novartis offers a copay assistance program for Leqvio for commercially insured patients. Federal anti-kickback statute rules prohibit Medicare beneficiaries from using manufacturer copay cards for Part D-covered drugs [15]. This prohibition applies regardless of whether the drug is on the formulary.

Patients who are Medicare-eligible but not yet enrolled (for example, those still covered by employer-sponsored insurance) may use the Novartis savings card if their plan is commercial and non-Medicare. Once Medicare becomes primary, that card cannot be used.

Novartis does operate a patient assistance program (PAP) for uninsured or underinsured patients. Medicare beneficiaries who meet income criteria may qualify for the PAP, which provides the drug at no cost through the prescriber's office. The Novartis patient support line for Leqvio is the appropriate contact for PAP eligibility screening.

What to Do If Coverage Is Denied and Appeals Fail

If all five appeal levels are exhausted and the denial stands, three options remain.

First, ask the prescriber whether evolocumab (Repatha) or alirocumab (Praluent) is a viable alternative. Both are PCSK9 monoclonal antibodies with strong LDL-C lowering data (evolocumab reduced LDL-C by 59% in the FOURIER trial [N=27,564] compared with placebo [16]), and both have better MA formulary coverage than inclisiran.

Second, evaluate ezetimibe. The IMPROVE-IT trial (N=18,144) showed ezetimibe 10 mg added to simvastatin reduced the composite cardiovascular endpoint by 6.4% relative risk reduction versus simvastatin alone over 7 years [17]. Ezetimibe is generic, inexpensive, and widely covered at Tier 1 or Tier 2.

Third, for patients with HeFH who cannot tolerate statins and who have exhausted non-formulary appeals, bempedoic acid (Nexletol) may be covered and provides LDL-C lowering of approximately 18 to 22% on top of background therapy [18].

Inclisiran Pharmacology and Why the Dosing Schedule Matters for Coverage

Inclisiran uses small interfering RNA (siRNA) to silence hepatic PCSK9 mRNA. This is mechanistically distinct from monoclonal antibodies: rather than blocking circulating PCSK9 protein, inclisiran prevents PCSK9 from being produced in liver cells [1]. The result is sustained LDL-C reduction that persists for approximately 6 months after each dose.

This pharmacology explains why the drug is clinician-administered and why it falls into the Part B gray zone. It also explains why the twice-yearly schedule is not merely a convenience: the drug's duration of action is built into its mechanism, not just its formulation [2]. That distinction matters when writing medical necessity letters arguing against step therapy through biweekly monoclonal antibodies.

The ORION-10 and ORION-11 trials reported low rates of injection-site reactions (2.6% inclisiran vs. 1.8% placebo) and no increase in hepatic enzyme elevations, myopathy, or new-onset diabetes compared with placebo [2]. Those safety data are relevant when a plan's denial letter cites "lack of safety data" as a reason for non-coverage.

Checking Your Specific Plan Before Each Injection

Formulary status can change mid-year under specific CMS-allowed circumstances, and PA criteria are updated annually at contract renewal. Confirming coverage before each of the twice-yearly injections prevents unexpected balance billing.

The minimum confirmation steps are:

• Log into the plan's online formulary tool or call member services with the drug name and NDC (inclisiran 284 mg/1.5 mL, NDC 0078-1032-61)
• Ask explicitly whether the drug is covered under the medical benefit (Part B) or the pharmacy benefit (Part D) for your plan ID
• Confirm that the current PA authorization is on file and has not expired
• Ask the administering clinic to verify the J-code and obtain a pre-service determination if Part B coverage is uncertain

The CMS Medicare Plan Finder at medicare.gov allows beneficiaries to compare formulary status across MA plans during the annual enrollment period (October 15 to December 7 each year) [10]. Switching to a plan with confirmed Part B inclisiran coverage during open enrollment is a legitimate and often overlooked strategy.